Department of Stem cells and Regenerative Medicine, D. Y. Patil University, Kolhapur, Maharashtra, India.
Laboratory Director, Reelabs Pvt. Ltd., Mumbai, Maharashtra, India.
JBRA Assist Reprod. 2022 Aug 4;26(3):482-491. doi: 10.5935/1518-0557.20210097.
Stem cells have been identified from various adult sources, including bone marrow, adipose tissue, and placenta, to name a few. Recently, the fallopian tube has also been identified as a novel source of therapeutics. However, the ability of stem cells from the fallopian tube mucosa to retain prolonged efficacy of proliferation and differentiation is yet to be explored. This forms the basis of the present study.
Stem cells isolated from the fallopian tube mucosa were tested for their marker characterization (markers of mesenchymal, pericyte, epithelial, and cell adhesion molecules) at various passages (P1, P3, P5, P10, P15). Proliferation, differentiation (osteoblast and adipocytes), and karyotyping were also carried out at both early (P3) and late (P15) passages.
Fallopian tube mucosa possesses mesenchymal stem cells, but they do not retain the ability to proliferate and differentiate beyond P15.
Although fallopian tube mucosal MSCs (FT-MMSCs) possess stem cell attributes, they cannot outweigh or be used in parallel to existing stem cell sources due to their inability to retain stemness characteristics beyond P15. Since FT-MMSC studies are in their infancy, further in-depth research is warranted to test whether FT-MMSCs have a use in bench to bedside applications. FT-MMSCs might be linked to tubal inflammation and fallopian tube hyperplasia, which contributes to a possible role in diagnostics and in providing insights for the betterment of womankind.
已从多种成人来源（包括骨髓、脂肪组织和胎盘等）中鉴定出干细胞。最近，输卵管也被鉴定为一种新的治疗来源。然而，输卵管黏膜中的干细胞是否能够保持长期增殖和分化的效力仍有待探索。这构成了本研究的基础。
从输卵管黏膜中分离出的干细胞，在不同的传代（P1、P3、P5、P10、P15）中进行了标志物特征（间充质标志物、周细胞、上皮标志物和细胞黏附分子）的测试。在早期（P3）和晚期（P15）传代时，还进行了增殖、分化（成骨细胞和脂肪细胞）和核型分析。
输卵管黏膜具有间充质干细胞，但它们在 P15 后不能保持增殖和分化的能力。
尽管输卵管黏膜间充质干细胞（FT-MMSCs）具有干细胞属性，但由于它们在 P15 后不能保持干细胞特征，因此不能替代或与现有的干细胞来源并用。由于 FT-MMSC 的研究仍处于起步阶段，因此需要进一步深入研究，以测试 FT-MMSCs 是否可用于从实验室到临床的应用。FT-MMSCs 可能与输卵管炎症和输卵管增生有关，这可能使其在诊断中具有一定作用，并为改善女性健康提供新的见解。
